BioArctic surges over 27% on deal with BMS

BioArctic shares surged over 27% after announcing a collaboration with Bristol Myers Squibb for two Alzheimer’s programs, highlighting potential transformative technology and financial backing.

Jefferies Upgrades Bristol Myers Squibb to ‘buy’ on drug Cobenfy

Jefferies upgraded Bristol-Myers Squibb to buy, raising its target to $70, citing confidence in its pipeline and product potential, especially for schizophrenia drug Cobenfy.

BofA reinstates pharma coverage

Bank of America reviews 11 U.S. pharma stocks, highlighting growth potential and challenges amid patent cliffs and pricing pressures while recommending buy, neutral, and underperform ratings.

Exclusive-Big hedge funds call on doctors, scientists for an edge on pharma, sources say

Street calls of the week

Wall Street analysts recap stock ratings and coverage updates, highlighting concerns and expectations for Alarm.com, Bristol-Myers Squibb, Axalta Coating Systems, Plug Power, and SolarEdge.

Bristol Myers faces renewed, $6.7 billion lawsuit over delayed cancer drug

Bristol Myers Squibb faces a $6.7 billion lawsuit for allegedly delaying drug approvals to avoid payouts to former Celgene shareholders, following a recent court dismissal.

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.69%

U.S. stocks rose on Monday, with the Dow reaching new heights; notable gains in Consumer Goods and Financial sectors, while some major players like Intel and Moderna faced declines.

AbbVie shares slip after schizophrenia drug trial misses primary endpoint

Earnings call: Bristol-Myers Squibb reports robust Q3 growth, raises guidance

Bristol-Myers Squibb reports a 20% revenue increase, FDA approvals, and strong guidance for growth while navigating challenges from generics and operational efficiency.

Bristol-Myers hikes annual earnings guidance as Q3 exceeds expectations; shares up

Bristol-Myers Squibb raised its 2024 earnings guidance after Q3 results exceeded expectations, with EPS at $1.80 and revenue hitting $11.9 billion, driven by U.S. growth.